**Name of Journal:** *World Journal of Methodology*

**Manuscript NO:** 63232

**Manuscript Type:** MINIREVIEWS

**Molecular and serology methods in the diagnosis of COVID-19: An overview**

Luz MS *et al.* Methods in the diagnosis of COVID-19

Marcel Silva Luz, Ronaldo Teixeira da Silva Júnior, Gabriella Almeida Santos de Santana, Gabriela Santos Rodrigues, Henrique de Lima Crivellaro, Mariana Santos Calmon, Clara Faria Souza Mendes dos Santos, Luis Guilherme de Oliveira Silva, Qesya Rodrigues Ferreira, Guilherme Rabelo Mota, Heloísa Heim, Filipe Antônio França da Silva, Breno Bittencourt de Brito, Fabrício Freire de Melo

**Marcel Silva Luz, Ronaldo Teixeira da Silva Júnior, Gabriella Almeida Santos de Santana, Gabriela Santos Rodrigues, Henrique de Lima Crivellaro, Mariana Santos Calmon, Clara Faria Souza Mendes dos Santos, Luis Guilherme de Oliveira Silva, Qesya Rodrigues Ferreira, Guilherme Rabelo Mota, Heloísa Heim, Filipe Antônio França da Silva, Breno Bittencourt de Brito,** Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45002175, Bahia, Brazil

**Fabrício Freire de Melo,** Instituto Multidisciplinar em Saúde , Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil

**Author contributions:** LuzMS contributed to the conceptualization, methodology, validation, investigation, and writing – original draft; da Silva Júnior RT contributed to the validation, visualization, formal analysis, writing – reviewing and editing; Santos de Santana GA, Rodrigues GS, Crivellaro HL, Calmon MS, dos Santos CFSM, Silva LGO, Ferreira QR, Mota GR, and Heim H contributed to the methodology, writing, visualization, investigation, and formal analysis; Silva FAF contributed to the methodology, visualization, investigation, and formal analysis; de Brito BB contributed to the methodology; de Melo FF contributed to the conceptualization, methodology, investigation, writing – original draft, and supervision.

**Corresponding author: Fabrício Freire de Melo, MSc, PhD, Postdoc, Professor,** Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58 - Candeias, Vitória da Conquista - BA, 45029-094, Vitória da Conquista 45029-094, Bahia, Brazil. freiremelo@yahoo.com.br

**Received:** January 26, 2021

**Revised:** July 31, 2021

**Accepted:** April 21, 2022

**Published online:** May 20, 2022

**Abstract**

Coronavirus disease-19 (COVID-19) has become a pandemic, being a global health concern since December 2019 when the first cases were reported. Severe acute respiratory syndrome coronavirus 2, the COVID-19 causal agent, is a β-coronavirus that has on its surface the spike protein, which helps in its virulence and pathogenicity towards the host. Thus, effective and applicable diagnostic methods to this disease come as an important tool for the management of the patients. The use of the molecular technique PCR, which allows the detection of the viral RNA through nasopharyngeal swabs, is considered the gold standard test for the diagnosis of COVID-19. Moreover, serological methods, such as enzyme-linked immunosorbent assays and rapid tests, are able to detect severe acute respiratory syndrome coronavirus 2-specific immunoglobulin A, immunoglobulin M, and immunoglobulin G in positive patients, being important alternative techniques for the diagnostic establishment and epidemiological surveillance. On the other hand, reverse transcription loop-mediated isothermal amplification also proved to be a useful diagnostic method for the infection, mainly because it does not require a sophisticated laboratory apparatus and has similar specificity and sensitivity to PCR. Complementarily, imaging exams provide findings of typical pneumonia, such as the ground-glass opacity radiological pattern on chest computed tomography scanning, which along with laboratory tests assist in the diagnosis of COVID-19.

**Key Words:** COVID-19; Pandemic; Diagnosis; Polymerase chain reaction; Molecular biology; Serology

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Luz MS, da Silva Júnior RT, Santos de Santana GA, Rodrigues GS, Crivellaro HL, Calmon MS, dos Santos CFSM, Silva LGO, Ferreira QR, Mota GR, Heim H, Silva FAFD, de Brito BB, de Melo FF. Molecular and serology methods in the diagnosis of COVID-19: An overview. *World J Methodol* 2022; 12(3): 83-91

**URL**: https://www.wjgnet.com/2222-0682/full/v12/i3/83.htm

**DOI**: https://dx.doi.org/10.5662/wjm.v12.i3.83

**Core Tip:** Severe acute respiratory syndrome coronavirus 2 is primarily detected by PCR, which is the gold standard diagnostic method to detect viral RNA. On the other hand, techniques such as serology with detection of immunoglobulin M and immunoglobulin G antibodies, imaging, and laboratory tests also assist in the diagnosis of severe acute respiratory syndrome coronavirus 2 infection. Moreover, the reverse transcription loop-mediated isothermal amplification has similar specificity and sensitivity to PCR. In this review, we discuss the main diagnostic methods and their uses in the current pandemic.

**INTRODUCTION**

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as responsible for severe cases of pneumonia in Wuhan, China, which culminated in the description of a new disease: coronavirus disease-19 (COVID-19)[1]. As a result of the large number of affected countries and high potential of viral infection, the World Health Organization declared COVID-19 as a pandemic in March 2020. Up to December 2020, 66243918 cases and 1528984 global deaths were officially confirmed[2]. SARS-CoV-2 is a single-stranded RNA, enveloped virus, which has the ability to attach to the angiotensin-converting enzyme 2 cell receptor due to the expression of the spike (S) protein on the viral envelope and then enter the host tissues[3]. The *Coronaviridae* family is made up of viruses historically known to cause diseases in animals and humans.The SARS and Middle East Respiratory Syndrome outbreak in 2002 and 2012, respectively, granted them wider visibility in the scientific community[4]. Furthermore, the dissemination potential of SARS-COV-2 is far higher than the others, due to structural differences in the S protein[5].

The most common signs and symptoms of COVID-19 include fever, dry cough, shortness of breath, myalgia, ageusia, anosmia, headache, rhinorrhea, nausea, vomiting, and diarrhea[6], and most patients showing severe symptoms are often affected by chronic disease. In addition, disturbed immune status, increased age, and obesity are strongly correlated to higher mortality rates[7]. Reverse transcription (RT)-PCR is considered the gold standard test for the diagnosis of COVID-19, due to its highly widespread and reliable technique performed in laboratories worldwide[8]. In addition, immunoenzymatic and immunochromatographic assays as well as reverse transcription loop-mediated isothermal amplification (RT-LAMP) are other diagnostic methods that have been applied in this field. Of note, clinical and epidemiological analysis, chest radiography and tomography, and laboratorial findings are crucial tools for an accurate diagnosis and appropriate evaluation of patients[9]. This article aimed to review the main aspects of COVID-19 diagnostic methods, providing updated information with an emphasis on molecular biology techniques and serology tests used in the detection of SARS-CoV-2 infection.

**RT-PCR**

RT-PCR is considered as the gold standard method in COVID-19 diagnosis, due to rapid detection with an average of 3-4 h and high sensibility and specificity[10]. The sample is usually taken through nasopharyngeal swab[11]. However, a systematic review and meta-analysis with 7 studies showed that bronchoalveolar lavage fluid had a higher positivity rate in the detection of SARS-CoV-2[12].

The test analysis usually starts from a sample collected from nasal and oropharyngeal swabs[13]. It is then divided in several steps that occur in different preset temperatures in order to provide RT and nucleic acid amplification[14]. The result is thus analyzed through probes marked with fluorescent dyes that enhance the sensitivity of the test[15]. The analysis of fecal samples, especially in children[16], may be used as well, as the virus can remain viable for approximately 5 wk after patient respiratory samples are negative for SARS-CoV-2 RNA[17].

RT-PCR is considered the actual main method as a result of its fastness, reproducibility, and mitigation of false-positive results[18]. The test shows good sensitivity and specificity, such as 94% and 100%, respectively (Table 1)[19-28]. Studies have also pointed to a level of detection that can vary from 3.8 to 23.0 copies/mL of viral RNA and showed no cross-reactivity with circulating respiratory viruses[20].

However, in a study with 610 patients from Wuhan, China, 18 patients had a positive RT-PCR result after two consecutive negative results, which might be owing to insufficient viral material, test handling error, or incorrect collection processing[21]. This is an alert to the need for a pattern in sampling procedures and alignment between the test and the patient’s clinical manifestation in order to achieve a higher diagnostic accuracy[22].

**RT-LAMP**

LAMP is a DNA amplification technique under isothermal conditions in a sample with 4 or 6 primers, which in contrast to RT-qPCR does not require a sophisticated laboratory apparatus, although it has similar specificity and sensitivity rates[29]. The visualization through pH-sensitive dyes, without the need of expensive instrumentation is also an advantage of this test[30]. As SARS-CoV-2 is an RNA virus, the test is therefore called RT-LAMP, due to the need for RTase to amplify RNA sequences[29].

The RT-LAMP is a fast test, providing results within 30 min[31]; moreover, unpurified samples can be directly used[32]. Studies also show that when the template has more than 200 copies of viral RNA, amplification curves appear within 15 min[33], which means an even quicker diagnosis. In addition, studies describe a level of detection of 2 copies of viral RNA in a 25 μl reaction[34], sensitivity rates that varies from 80%[26] to 97.5%[27], concomitantly with no cross-reactivity with other respiratory pathogens (high specificity)[33,35] and lower cost, all of which endorses that the diagnosis of COVID-19 through LAMP needs to be considered[36,37].

However, a meta-analysis including 138 articles showed that RT-LAMP sensitivity (86.3%) is lower than that of RT-PCR (96.2%)[38]. Furthermore, carry-over contamination, which can lead to false positive results, are common in LAMP reactions, probably as a consequence of aerosol formed from the products of the test[34].This phenomenon highlights the need of laboratories with good practice of molecular biology and separate spaces to deal with the components of the test as well as more studies about the efficacy of all types of genes and primers used in this test.

**SEROLOGICAL TESTS**

Serological tests have become even more available during the COVID-19 pandemic. Consequently, research on their role as auxiliary diagnostic methods for SARS-CoV-2 infection has experienced exponential growth[39]. Thereby, these tests may support the COVID-19 diagnosis, especially when there is a longer period of symptoms with negative RT-PCR assays in a patient with a suspected infection by SARS-CoV-2[40]. Moreover, its use allied to RT-PCR greatly increases the diagnostic sensitivity[41].

Among the serological tests commonly used for diagnosis of COVID-19, the ELISA, the chemiluminescence immunoassay (CLIA), and the lateral flow immunochromatographic assay (LFA) stand out. The ease, agility, and point-of-care testing are great advantages associated with the use of these tests[42]. However, they may often show low sensitivity, require specialized equipment[39,42], or have cross-reactivity with other pathogens, such as SARS-CoV-1[43]. A study also showed a cross-reactivity of 26% in serological tests for COVID-19 during acute Zika virus infection[44].

The sensitivity of the test is strictly related to the elapsed time from the beginning of symptoms, being more useful 15 d after the onset of clinical manifestations, especially regarding the detection of isolated immunoglobulin (Ig) G[45]. In that context, a meta-analysis including 40 studies evaluated the presence of anti-SARS-CoV-2 IgG during the first symptomatic week, and the rates of false-negative diagnoses ranged from 44% to 87%[46]. Therefore, simultaneous analysis of IgM and IgG antibodies, as they have different emergence times, may increase the serological test sensitivity[39,47]. Although some studies compare IgG with other antibodies, such as IgA, to analyze any increase in the effectiveness of serological surveillance, the results are not promising[48].

The overall specificity for all types of antibodies was higher than 98%. The average sensitivity for IgG detection ranges from 80% to 85%, with CLIA being the most sensitive, followed by ELISA, and with much lower performance the LFA test[42,45]. IgM evaluation showed a sensitivity of 80.9% for CLIA, 84.5% for ELISA, and 51.4% with LFA. This study also demonstrated that in the use of combined IgM/IgG tests, the CLIA performance was higher than ELISA and LFA, with results of 97.3%, 90.5% and 85.8%, respectively[45].

Sensitivity and specificity differences according to the viral protein analyzed are also documented: S protein is more specific, but the nucleocapsid and receptor-binding domain proteins are more sensitive in patients with mild infection[47,49]. Therefore, research on antibodies against different antigens may be useful in order to improve diagnostic methods, avoid false-negatives, and reach a higher diagnostic accuracy.

**ANTIGEN DETECTION METHODS**

Viral antigen is a molecule with immunogenic potential that can be targeted by diagnostic tests through a reaction with monoclonal antibodies. Several antigen detection tests have been developed as alternatives for the rapid diagnosis of the COVID-19[50,51]. The results of the test with nasopharyngeal secretions are ready within 15 min[52], and it can be performed either through immunochromatography, with rapid detection, or ELISA with better sensitivity[50].

The average sensitivity of antigen detection tests is around 50%–70%, and they are 100% specific[51,53]. Of note, the performance of those tests may be influenced by higher or lower viral loads as well as by the specific antigen used. In that context, studies have shown different results when this method was evaluated, and the sensitivity values varied from 30.2%[52] to 93.9%[54] Overall, higher rates of accurate diagnosis in antigen tests were greatly correlated with early infection, when the viral load of the upper respiratory tract is higher[55].

Therefore, although the COVID-19 diagnosis through antigen detection has a high specificity and is faster and cheaper than RT-PCR, the precise time of usage of this test is crucial for proper detection of the virus antigens[52]. That said, the current gold standard diagnostic test for COVID-19 is still more reliable because its use is associated with lower rates of false negative results[56]. Nevertheless, utilization of antigen detection tests, with additional research, could turn into a viable option in the current pandemic context.

**COMPLEMENTARY DIAGNOSTIC METHODS**

***Chest computed tomography findings***

Chest computed tomography (CT) has been used as an alternative and complementary method for COVID-19 diagnosis since CTs can detect pulmonary abnormalities even when RT-PCR results turn negative[57] for highly suspect cases with clinical symptoms[58] in the early days of infection[59].

The chest CT diagnosis works through analysis of the variation in imaging findings that occur according to the disease progression and severity[60]. The pulmonary imaging abnormalities start to appear around 4 d after the first symptoms, and their findings are more visible following the second week of clinical manifestations[58].

Accordingly, the most predominant COVID-19 pneumonia imaging changes are ground-glass opacity lesions with or without consolidations, peripheral and bilateral lung distribution of the disease, and multilobar lung involvement, predominantly in the lower lobes[61,62]. Some less common CT manifestations are the crazy-paving pattern, ground-glass opacity with consolidation, interlobular septal thickening, and pleural effusion[63]. Chest CT scans are highly sensitive to COVID-19 lung abnormalities[64], mainly in high-risk symptomatic cases[65].

However, these imaging findings have low specificity[63]. A study performed with 1014 patients showed an average specificity of 25%[28], probably due to other viral pneumonias leading to similar imaging alterations, a fact that limits the use of this method in areas with high prevalence of other respiratory tract infections[64]. Moreover, chest CT exams can detect no abnormalities in some asymptomatic or mild symptomatic cases[63],making CT scans more of a complementary diagnostic test than a definitive one. Table 1 summarizes the sensitivity, specificity, time to result, and limitations of the diagnostic methods discussed in this review so far.

***Laboratory findings***

Patient reports from Wuhan showed recurrent cases of lymphocytopenia since the beginning of the infections in China[66]. Besides that, studies also show a relevant frequency of patients with leukocytosis during SARS-CoV-2 infection[67]. A meta-analysis showed that non-surviving patients had an expressive increase in leukocyte count, total bilirubin, serum ferritin, and interleukin 6 as well as a reduced lymphocyte count[68]. Thus, leukocyte series elevation can represent worse prognostic and high risk of unfavorable outcomes.

Increases in the levels of lactate dehydrogenase and C-reactive protein were also highlighted and associated with pulmonary and myocardial lesions, especially in severe patients[69]. Low serum albumin rates and high levels of alanine aminotransferase and aspartate aminotransferase points to possible liver complications, which is very common in acute phases of the disease in patients with a severe infection[70,71]. Furthermore, the association of these points with elevation in renal biomarkers (for example, creatinine), coagulation measures, and heart and muscle injury scores suggest potential progression to multiple organ failure in severe patients[68]. Thereby, elevated levels of D-dimer, fibrin degradation products, and fibrinogen can be observed during the course of the disease, with the D-dimer alterations being the most common[72]. A study related that levels of these coagulation parameters were observed in severe patients with worse prognosis, while mild disease or early stage patients had normal ranges[73,74]. In addition, thrombocytopenia is also a possible laboratory finding in COVID-19. A meta-analysis reported that platelet count was minor in severe disease and even smaller in non-surviving patients[74]. These findings might be indicative of disease progression and coagulation disorders, which means that the tracking of these signs is very important while managing patients[74,75].

Moreover, possible coinfections of SARS-CoV-2 and bacterial infections might cause neutrophilia and leukocytosis, associated with lymphocytopenia, without increasing inflammatory factors, such as D-dimer and C-reactive protein[76]. Therefore, laboratory findings have proven to be a helpful option as a complementary diagnosis. It is also suitable in the visualization of possible comorbidities in patients with COVID-19 and as an indicator of disease severity.

Several studies are being carried out to test the efficacy of drugs, foods, and mineral supplements against COVID-19. Lymecycline and famotidine, for example, are being studied as a potential treatment for COVID-19[77,78], due to a possible ability to bind some SARS-CoV-2 structures (Mpro, S protein, RdRp, and furin) and have an anti-inflammatory action[79], respectively. However, there is, up to this moment, not enough evidence and controlled clinical trials to affirm its efficacy against the disease. In addition, mineral supplements such as zinc apparently have some antiviral properties that could be used against SARS-CoV-2 infection, such as a capability of modulating the host’s immune response and attenuating the cytokine storm caused by COVID-19[80]. However, a randomized clinical trial of 214 patients showed that zinc supplementation had no significant benefits[81].

**CONCLUSION**

Notably, the use of serology and antigen detection tests have important limitations since false negative results are common. Nonetheless, in a pandemic context, these methods are crucial for epidemiological surveillance. RT-PCR remains the gold standard test and should be preferred to diagnose COVID-19. However, the high potential of RT-LAMP, given that it is a fast and affordable test, should be considered in diagnostic propedeutics. In addition, the laboratory and imaging findings play important roles as complementary diagnostic tools aiding in patient management.

**REFERENCES**

1 **Zhu N**, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; **382**: 727-733 [PMID: 31978945 DOI: 10.1056/NEJMoa2001017]

2 **World Health Organization**. Coronavirus disease 2019 (COVID-19) situation reports. [cited December 8, 2020]. In: who.int [Internet]. Geneva: World Health Organization, 2020. Available from: URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

3 **Yuki K**, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clin Immunol* 2020; **215**: 108427 [PMID: 32325252 DOI: 10.1016/j.clim.2020.108427]

4 **Banerjee A**, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and Coronaviruses. *Viruses* 2019; **11** [PMID: 30634396 DOI: 10.3390/v11010041]

5 **Rabaan AA**, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, Dhama K, Yatoo MI, Bonilla-Aldana DK, Rodriguez-Morales AJ. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. *Infez Med* 2020; **28**: 174-184 [PMID: 32275259]

6 **Yan Y**, Shin WI, Pang YX, Meng Y, Lai J, You C, Zhao H, Lester E, Wu T, Pang CH. The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. *Int J Environ Res Public Health* 2020; **17** [PMID: 32235575 DOI: 10.3390/ijerph17072323]

7 **Chen N**, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**: 507-513 [PMID: 32007143 DOI: 10.1016/S0140-6736(20)30211-7]

8 **Mahendiratta S**, Batra G, Sarma P, Kumar H, Bansal S, Kumar S, Prakash A, Sehgal R, Medhi B. Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review. *Life Sci* 2020; **258**: 118207 [PMID: 32777301 DOI: 10.1016/j.lfs.2020.118207]

9 **Oliveira BA**, Oliveira LC, Sabino EC, Okay TS. SARS-CoV-2 and the COVID-19 disease: a mini review on diagnostic methods. *Rev Inst Med Trop Sao Paulo* 2020; **62**: e44 [PMID: 32609256 DOI: 10.1590/S1678-9946202062044]

10 **Tahamtan A**, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. *Expert Rev Mol Diagn* 2020; **20**: 453-454 [PMID: 32297805 DOI: 10.1080/14737159.2020.1757437]

11 **Holshue ML**, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med* 2020; **382**: 929-936 [PMID: 32004427 DOI: 10.1056/NEJMoa2001191]

12 **Bwire GM**, Majigo MV, Njiro BJ, Mawazo A. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis. *J Med Virol* 2021; **93**: 719-725 [PMID: 32706393 DOI: 10.1002/jmv.26349]

13 **Poljak M**, Korva M, Knap Gašper N, Fujs Komloš K, Sagadin M, Uršič T, Avšič Županc T, Petrovec M. Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic. *J Clin Microbiol* 2020; **58** [PMID: 32277022 DOI: 10.1128/jcm.00599-20]

14 **Chan JF**, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020; **395**: 514-523 [PMID: 31986261 DOI: 10.1016/S0140-6736(20)30154-9]

15 **Kubista M**, Andrade JM, Bengtsson M, Forootan A, Jonák J, Lind K, Sindelka R, Sjöback R, Sjögreen B, Strömbom L, Ståhlberg A, Zoric N. The real-time polymerase chain reaction. *Mol Aspects Med* 2006; **27**: 95-125 [PMID: 16460794 DOI: 10.1016/j.mam.2005.12.007]

16 **Xing YH**, Ni W, Wu Q, Li WJ, Li GJ, Wang WD, Tong JN, Song XF, Wing-Kin Wong G, Xing QS. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. *J Microbiol Immunol Infect* 2020; **53**: 473-480 [PMID: 32276848 DOI: 10.1016/j.jmii.2020.03.021]

17 **Wu Y**, Guo C, Tang L, Hong Z, Zhou J, Dong X, Yin H, Xiao Q, Tang Y, Qu X, Kuang L, Fang X, Mishra N, Lu J, Shan H, Jiang G, Huang X. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020; **5**: 434-435 [PMID: 32199469 DOI: 10.1016/S2468-1253(20)30083-2]

18 **Shen M**, Zhou Y, Ye J, Abdullah Al-Maskri AA, Kang Y, Zeng S, Cai S. Recent advances and perspectives of nucleic acid detection for coronavirus. *J Pharm Anal* 2020; **10**: 97-101 [PMID: 32292623 DOI: 10.1016/j.jpha.2020.02.010]

19 **Suo T**, Liu X, Feng J, Guo M, Hu W, Guo D, Ullah H, Yang Y, Zhang Q, Wang X, Sajid M, Huang Z, Deng L, Chen T, Liu F, Xu K, Liu Y, Zhang Q, Liu Y, Xiong Y, Chen G, Lan K, Chen Y. ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. *Emerg Microbes Infect* 2020; **9**: 1259-1268 [PMID: 32438868 DOI: 10.1080/22221751.2020.1772678]

20 **van Kasteren PB**, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den Brandt A, Molenkamp R, Reusken CBEM, Meijer A. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. *J Clin Virol* 2020; **128**: 104412 [PMID: 32416600 DOI: 10.1016/j.jcv.2020.104412]

21 **Li Y**, Yao L, Li J, Chen L, Song Y, Cai Z, Yang C. Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. *J Med Virol* 2020; **92**: 903-908 [PMID: 32219885 DOI: 10.1002/jmv.25786]

22 **Wang Y**, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. *J Med Virol* 2020; **92**: 538-539 [PMID: 32096564 DOI: 10.1002/jmv.25721]

23 **Liu W**, Liu L, Kou G, Zheng Y, Ding Y, Ni W, Wang Q, Tan L, Wu W, Tang S, Xiong Z, Zheng S. Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2. *J Clin Microbiol* 2020; **58** [PMID: 32229605 DOI: 10.1128/jcm.00461-20]

24 **Cai XF**, Chen J, Li Hu J, Long QX, Deng HJ, Liu P, Fan K, Liao P, Liu BZ, Wu GC, Chen YK, Li ZJ, Wang K, Zhang XL, Tian WG, Xiang JL, Du HX, Wang J, Hu Y, Tang N, Lin Y, Ren JH, Huang LY, Wei J, Gan CY, Chen YM, Gao QZ, Chen AM, He CL, Wang DX, Hu P, Zhou FC, Huang AL, Wang DQ. A Peptide-Based Magnetic Chemiluminescence Enzyme Immunoassay for Serological Diagnosis of Coronavirus Disease 2019. *J Infect Dis* 2020; **222**: 189-193 [PMID: 32382737 DOI: 10.1093/infdis/jiaa243]

25 **Montesinos I**, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, Carbone V, Vandenberg O, Gulbis B, Wolff F, Rodriguez-Villalobos H. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. *J Clin Virol* 2020; **128**: 104413 [PMID: 32403010 DOI: 10.1016/j.jcv.2020.104413]

26 **Österdahl MF**, Lee KA, Lochlainn MN, Wilson S, Douthwaite S, Horsfall R, Sheedy A, Goldenberg SD, Stanley CJ, Spector TD, Steves CJ. Detecting SARS-CoV-2 at point of care: preliminary data comparing loop-mediated isothermal amplification (LAMP) to polymerase chain reaction (PCR). *BMC Infect Dis* 2020; **20**: 783 [PMID: 33081710 DOI: 10.1186/s12879-020-05484-8]

27 **Dao Thi VL**, Herbst K, Boerner K, Meurer M, Kremer LP, Kirrmaier D, Freistaedter A, Papagiannidis D, Galmozzi C, Stanifer ML, Boulant S, Klein S, Chlanda P, Khalid D, Barreto Miranda I, Schnitzler P, Kräusslich HG, Knop M, Anders S. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci Transl Med* 2020; **12** [PMID: 32719001 DOI: 10.1126/scitranslmed.abc7075]

28 **Ai T**, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology* 2020; **296**: E32-E40 [PMID: 32101510 DOI: 10.1148/radiol.2020200642]

29 **Notomi T**, Okayama H, Masubuchi H, Yonekawa T, Watanabe K, Amino N, Hase T. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res* 2000; **28**: E63 [PMID: 10871386 DOI: 10.1093/nar/28.12.e63]

30 **Tanner NA**, Zhang Y, Evans TC Jr. Visual detection of isothermal nucleic acid amplification using pH-sensitive dyes. *Biotechniques* 2015; **58**: 59-68 [PMID: 25652028 DOI: 10.2144/000114253]

31 **Tomita N**, Mori Y, Kanda H, Notomi T. Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products. *Nat Protoc* 2008; **3**: 877-882 [PMID: 18451795 DOI: 10.1038/nprot.2008.57]

32 **Nie K**, Qi SX, Zhang Y, Luo L, Xie Y, Yang MJ, Zhang Y, Li J, Shen H, Li Q, Ma XJ. Evaluation of a direct reverse transcription loop-mediated isothermal amplification method without RNA extraction for the detection of human enterovirus 71 subgenotype C4 in nasopharyngeal swab specimens. *PLoS One* 2012; **7**: e52486 [PMID: 23272248 DOI: 10.1371/journal.pone.0052486]

33 **Lu R**, Wu X, Wan Z, Li Y, Jin X, Zhang C. A Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. *Int J Mol Sci* 2020; **21** [PMID: 32325642 DOI: 10.3390/ijms21082826]

34 **Huang WE**, Lim B, Hsu CC, Xiong D, Wu W, Yu Y, Jia H, Wang Y, Zeng Y, Ji M, Chang H, Zhang X, Wang H, Cui Z. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2. *Microb Biotechnol* 2020; **13**: 950-961 [PMID: 32333644 DOI: 10.1111/1751-7915.13586]

35 **Yan C**, Cui J, Huang L, Du B, Chen L, Xue G, Li S, Zhang W, Zhao L, Sun Y, Yao H, Li N, Zhao H, Feng Y, Liu S, Zhang Q, Liu D, Yuan J. Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect* 2020; **26**: 773-779 [PMID: 32276116 DOI: 10.1016/j.cmi.2020.04.001]

36 **Baek YH**, Um J, Antigua KJC, Park JH, Kim Y, Oh S, Kim YI, Choi WS, Kim SG, Jeong JH, Chin BS, Nicolas HDG, Ahn JY, Shin KS, Choi YK, Park JS, Song MS. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. *Emerg Microbes Infect* 2020; **9**: 998-1007 [PMID: 32306853 DOI: 10.1080/22221751.2020.1756698]

37 **Mautner L**, Baillie CK, Herold HM, Volkwein W, Guertler P, Eberle U, Ackermann N, Sing A, Pavlovic M, Goerlich O, Busch U, Wassill L, Huber I, Baiker A. Rapid point-of-care detection of SARS-CoV-2 using reverse transcription loop-mediated isothermal amplification (RT-LAMP). *Virol J* 2020; **17**: 160 [PMID: 33087160 DOI: 10.1186/s12985-020-01435-6]

38 **Mustafa Hellou M**, Górska A, Mazzaferri F, Cremonini E, Gentilotti E, De Nardo P, Poran I, Leeflang MM, Tacconelli E, Paul M. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. *Clin Microbiol Infect* 2021; **27**: 341-351 [PMID: 33188933 DOI: 10.1016/j.cmi.2020.11.002]

39 **Li C**, Zhao C, Bao J, Tang B, Wang Y, Gu B. Laboratory diagnosis of coronavirus disease-2019 (COVID-19). *Clin Chim Acta* 2020; **510**: 35-46 [PMID: 32621814 DOI: 10.1016/j.cca.2020.06.045]

40 **Tang MS**, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth CW. Clinical Performance of Two SARS-CoV-2 Serologic Assays. *Clin Chem* 2020; **66**: 1055-1062 [PMID: 32402061 DOI: 10.1093/clinchem/hvaa120]

41 **Long QX**, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020; **26**: 1200-1204 [PMID: 32555424 DOI: 10.1038/s41591-020-0965-6]

42 **Nicol T**, Lefeuvre C, Serri O, Pivert A, Joubaud F, Dubée V, Kouatchet A, Ducancelle A, Lunel-Fabiani F, Le Guillou-Guillemette H. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). *J Clin Virol* 2020; **129**: 104511 [PMID: 32593133 DOI: 10.1016/j.jcv.2020.104511]

43 **Singh A**, Shaikh A, Singh R, Singh AK. COVID-19: From bench to bed side. *Diabetes Metab Syndr* 2020; **14**: 277-281 [PMID: 32283498 DOI: 10.1016/j.dsx.2020.04.011]

44 **Faccini-Martínez ÁA**, Rivero R, Garay E, García A, Mattar S, Botero Y, Galeano K, Miranda J, Martínez C, Guzmán C, Arrieta G, Contreras H, Kerguelen H, Moscote M, Brango E, Contreras V. Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia. *Int J Infect Dis* 2020; **101**: 191-193 [PMID: 33002616 DOI: 10.1016/j.ijid.2020.09.1451]

45 **Deeks JJ**, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Dittrich S, Emperador D, Hooft L, Leeflang MM, Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Antibody tests for identification of current and past infection with SARS-CoV-2. *Cochrane Database Syst Rev* 2020; **6**: CD013652 [PMID: 32584464 DOI: 10.1002/14651858.CD013652]

46 **Lisboa Bastos M**, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, Lan Z, Law S, MacLean E, Trajman A, Menzies D, Benedetti A, Ahmad Khan F. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ* 2020; **370**: m2516 [PMID: 32611558 DOI: 10.1136/bmj.m2516]

47 **Espejo AP**, Akgun Y, Al Mana AF, Tjendra Y, Millan NC, Gomez-Fernandez C, Cray C. Review of Current Advances in Serologic Testing for COVID-19. *Am J Clin Pathol* 2020; **154**: 293-304 [PMID: 32583852 DOI: 10.1093/ajcp/aqaa112]

48 **Beavis KG**, Matushek SM, Abeleda APF, Bethel C, Hunt C, Gillen S, Moran A, Tesic V. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. *J Clin Virol* 2020; **129**: 104468 [PMID: 32485620 DOI: 10.1016/j.jcv.2020.104468]

49 **Okba NMA**, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, Lamers MM, Sikkema RS, de Bruin E, Chandler FD, Yazdanpanah Y, Le Hingrat Q, Descamps D, Houhou-Fidouh N, Reusken CBEM, Bosch BJ, Drosten C, Koopmans MPG, Haagmans BL. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis* 2020; **26**: 1478-1488 [PMID: 32267220 DOI: 10.3201/eid2607.200841]

50 **Yüce M**, Filiztekin E, Özkaya KG. COVID-19 diagnosis -A review of current methods. *Biosens Bioelectron* 2021; **172**: 112752 [PMID: 33126180 DOI: 10.1016/j.bios.2020.112752]

51 **Chaimayo C**, Kaewnaphan B, Tanlieng N, Athipanyasilp N, Sirijatuphat R, Chayakulkeeree M, Angkasekwinai N, Sutthent R, Puangpunngam N, Tharmviboonsri T, Pongraweewan O, Chuthapisith S, Sirivatanauksorn Y, Kantakamalakul W, Horthongkham N. Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand. *Virol J* 2020; **17**: 177 [PMID: 33187528 DOI: 10.1186/s12985-020-01452-5]

52 **Scohy A**, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. *J Clin Virol* 2020; **129**: 104455 [PMID: 32485618 DOI: 10.1016/j.jcv.2020.104455]

53 **Hirotsu Y**, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, Sueki H, Hayakawa M, Mochizuki H, Tsutsui T, Kakizaki Y, Miyashita Y, Yagi S, Kojima S, Omata M. Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients. *Int J Infect Dis* 2020; **99**: 397-402 [PMID: 32800855 DOI: 10.1016/j.ijid.2020.08.029]

54 **Porte L**, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, Pizarro G, Vial P, Iruretagoyena M, Dittrich S, Weitzel T. Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. *Int J Infect Dis* 2020; **99**: 328-333 [PMID: 32497809 DOI: 10.1016/j.ijid.2020.05.098]

55 **Lambert-Niclot S**, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso AM, Le Goff J, Delaugerre C. Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. *J Clin Microbiol* 2020; **58** [PMID: 32404480 DOI: 10.1128/JCM.00977-20]

56 **Mak GC**, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, Chan RC, Tsang DN. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J Clin Virol* 2020; **129**: 104500 [PMID: 32585619 DOI: 10.1016/j.jcv.2020.104500]

57 **Manigandan S**, Wu MT, Ponnusamy VK, Raghavendra VB, Pugazhendhi A, Brindhadevi K. A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19. *Process Biochem* 2020; **98**: 233-240 [PMID: 32843849 DOI: 10.1016/j.procbio.2020.08.016]

58 **Salehi S**, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. *AJR Am J Roentgenol* 2020; **215**: 87-93 [PMID: 32174129 DOI: 10.2214/AJR.20.23034]

59 **Wan S**, Li M, Ye Z, Yang C, Cai Q, Duan S, Song B. CT Manifestations and Clinical Characteristics of 1115 Patients with Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis. *Acad Radiol* 2020; **27**: 910-921 [PMID: 32505599 DOI: 10.1016/j.acra.2020.04.033]

60 **Awulachew E**, Diriba K, Anja A, Getu E, Belayneh F. Computed Tomography (CT) Imaging Features of Patients with COVID-19: Systematic Review and Meta-Analysis. *Radiol Res Pract* 2020; **2020**: 1023506 [PMID: 32733706 DOI: 10.1155/2020/1023506]

61 **Tsikala Vafea M**, Atalla E, Kalligeros M, Mylona EK, Shehadeh F, Mylonakis E. Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis. *Clin Radiol* 2020; **75**: 876.e33-876.e39 [PMID: 32861461 DOI: 10.1016/j.crad.2020.07.025]

62 **Altmayer S**, Zanon M, Pacini GS, Watte G, Barros MC, Mohammed TL, Verma N, Marchiori E, Hochhegger B. Comparison of the computed tomography findings in COVID-19 and other viral pneumonia in immunocompetent adults: a systematic review and meta-analysis. *Eur Radiol* 2020; **30**: 6485-6496 [PMID: 32594211 DOI: 10.1007/s00330-020-07018-x]

63 **Sun Z**, Zhang N, Li Y, Xu X. A systematic review of chest imaging findings in COVID-19. *Quant Imaging Med Surg* 2020; **10**: 1058-1079 [PMID: 32489929 DOI: 10.21037/qims-20-564]

64 **Adams HJA**, Kwee TC, Yakar D, Hope MD, Kwee RM. Systematic Review and Meta-Analysis on the Value of Chest CT in the Diagnosis of Coronavirus Disease (COVID-19): *Sol Scientiae, Illustra Nos*. *AJR Am J Roentgenol* 2020; **215**: 1342-1350 [PMID: 32478562 DOI: 10.2214/AJR.20.23391]

65 **Bao C**, Liu X, Zhang H, Li Y, Liu J. Coronavirus Disease 2019 (COVID-19) CT Findings: A Systematic Review and Meta-analysis. *J Am Coll Radiol* 2020; **17**: 701-709 [PMID: 32283052 DOI: 10.1016/j.jacr.2020.03.006]

66 **Huang C**, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; **395**: 497-506 [PMID: 31986264 DOI: 10.1016/S0140-6736(20)30183-5]

67 **Pourbagheri-Sigaroodi A**, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. *Clin Chim Acta* 2020; **510**: 475-482 [PMID: 32798514 DOI: 10.1016/j.cca.2020.08.019]

68 **Henry BM**, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med* 2020; **58**: 1021-1028 [PMID: 32286245 DOI: 10.1515/cclm-2020-0369]

69 **Wang Z**, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. *Clin Infect Dis* 2020; **71**: 769-777 [PMID: 32176772 DOI: 10.1093/cid/ciaa272]

70 **Wan S**, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y, Huang X, Lv J, Luo Y, Shen L, Yang H, Huang G, Yang R. Clinical features and treatment of COVID-19 patients in northeast Chongqing. *J Med Virol* 2020; **92**: 797-806 [PMID: 32198776 DOI: 10.1002/jmv.25783]

71 **Zhang C**, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020; **5**: 428-430 [PMID: 32145190 DOI: 10.1016/S2468-1253(20)30057-1]

72 **Lazzaroni MG**, Piantoni S, Masneri S, Garrafa E, Martini G, Tincani A, Andreoli L, Franceschini F. Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. *Blood Rev* 2021; **46**: 100745 [PMID: 32868115 DOI: 10.1016/j.blre.2020.100745]

73 **Tang N**, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost* 2020; **18**: 844-847 [PMID: 32073213 DOI: 10.1111/jth.14768]

74 **Lippi G**, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta* 2020; **506**: 145-148 [PMID: 32178975 DOI: 10.1016/j.cca.2020.03.022]

75 **Han H**, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med* 2020; **58**: 1116-1120 [PMID: 32172226 DOI: 10.1515/cclm-2020-0188]

76 **Dong X**, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, Akdis CA, Gao YD. Eleven faces of coronavirus disease 2019. *Allergy* 2020; **75**: 1699-1709 [PMID: 32196678 DOI: 10.1111/all.14289]

77 **Sodhi M**, Etminan M. Therapeutic Potential for Tetracyclines in the Treatment of COVID-19. *Pharmacotherapy* 2020; **40**: 487-488 [PMID: 32267566 DOI: 10.1002/phar.2395]

78 **Ortega JT**, Serrano ML, Jastrzebska B. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis. *Biomolecules* 2020; **10** [PMID: 32599963 DOI: 10.3390/biom10060954]

79 **Naveja JJ**, Madariaga-Mazón A, Flores-Murrieta F, Granados-Montiel J, Maradiaga-Ceceña M, Alaniz VD, Maldonado-Rodriguez M, García-Morales J, Senosiain-Peláez JP, Martinez-Mayorga K. Union is strength: antiviral and anti-inflammatory drugs for COVID-19. *Drug Discov Today* 2021; **26**: 229-239 [PMID: 33127568 DOI: 10.1016/j.drudis.2020.10.018]

80 **Rani I**, Goyal A, Bhatnagar M, Manhas S, Goel P, Pal A, Prasad R. Potential molecular mechanisms of zinc- and copper-mediated antiviral activity on COVID-19. *Nutr Res* 2021; **92**: 109-128 [PMID: 34284268 DOI: 10.1016/j.nutres.2021.05.008]

81 **Thomas S**, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, Il'Giovine ZJ, Mehra R, McWilliams C, Nissen SE, Desai MY. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial. *JAMA Netw Open* 2021; **4**: e210369 [PMID: 33576820 DOI: 10.1001/jamanetworkopen.2021.0369]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior author or other co-authors who contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model**: Single blind

**Peer-review started:** January 26, 2021

**First decision:** July 18, 2021

**Article in press:** April 21, 2022

**Specialty type:** Infectious diseases

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Pal A,India **S-Editor:** Ma YJ **L-Editor:** Filipodia **P-Editor:** Ma YJ

**Table 1 Coronavirus disease 2019 main diagnostic methods characteristics**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Diagnostic method** | **Sensitivity** | **Specificity** | **Time to result** |
| Liu *et al*[23] | ELISA (IgM/IgG) | 57.9%-90.7% | No cross-reactivity observed | About 100 min |
| Cai *et al*[24] | CLIA (IgM/IgG/IgM and IgG) | 57.2%-81.5% | No cross-reactivity observed | ND |
| Montesinos *et al*[25] | LFA (IgM/IgG/IgM and IgG) | ~70.0% | 95.8%-100% | About 10 min |
| Scohy *et al*[52] | Antigen detection | 30.2% | 100% | About 15 min |
| Porte *et al*[54] | Antigen detection | 93.9% | 100% | About 15 min |
| Suo *et al*[19] | RT-PCR | 94.0% | 100% | ND |
| Österdahl *et al*[26] | RT-LAMP | 80.0% | 73%–100% | About 25 min |
| Dao Thi *et al*[27] | RT-LAMP | 97.5% | 99.7% | About 30 min |
| Ai *et al*[28] | Chest CT | 97.0% | 25% | ND |

ELISA: Enzyme-linked immunosorbent assay; IgA: Immunoglobulin A; IgM: Immunoglobulin M; IgG: Immunoglobulin G; LFA: Lateral flow assay; CLIA: Chemiluminescence immunoassay; RT-PCR: Reverse transcription-polymerase chain reaction; RT-LAMP: Reverse transcription loop-mediated isothermal amplification; CT: Computed tomography; ND: not described.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**